Clinical Trial

Transcranial Static Magnetic Stimulation (tSMS) in Huntington's Disease (HD)

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 16, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Huntington's disease (HD) is a neurodegenerative pathology characterized by choreic hyperkinesias which represent the typical motor symptom and are represented by involuntary, aimless, irregular, recurrent, unpredictable and non-rhythmic movements of the trunk, face and limbs. Non-invasive brain neuromodulation has been proposed as a possible treatment for involuntary movements in several clinical conditions including HD. The objective of the study is to evaluate the effect of home treatment with repeated sessions of transcranial static magnetic field stimulation (tSMS) in safely reducing choreic hyperkinesis in HD patients.
Trial Details
NCT Number NCT06976983
Lead Sponsor Neuromed IRCCS
Conditions Huntington Disease
Enrollment 30 participants
Start Date 2025-09-01
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-16